scholarly journals High Expression of lncRNA HEIH is Helpful in the Diagnosis of Non-Small Cell Lung Cancer and Predicts Poor Prognosis

2021 ◽  
Author(s):  
Chaowen He ◽  
Dongxuan Huang ◽  
Fan Yang ◽  
Dongsheng Huang ◽  
Yahui Cao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Roc Curve ◽  
Peripheral Blood ◽  
Poor Prognosis ◽  
Small Cell ◽  
High Expression ◽  
Small Cell Lung ◽  
Low Expression

Abstract Objective: This study aims to investigate the expression and clinical value of long non-coding RNA (lncRNA) HEIH in peripheral blood of patients with non-small cell lung cancer (NSCLC).Methods: Healthy subjects (N=70), patients with lung squamous cell carcinoma (LUSC, N=70) and patients with lung adenocarcinoma (LUAD, N=80) were included. LncRNA HEIH expression in peripheral blood of included subjects was detected. According to the median expression of lncRNA HEIH, LUSC and LUAD patients were divided into lncRNA HEIH high/low expression group. The correlation between lncRNA HEIH and clinical indicators of patients was analyzed. Receiver-operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of lncRNA HEIH and carcinoembryonic antigen (CEA) in LUSC and LUAD patients. MedCalc-Comparison of ROC curves was used to compare the area under ROC curve. The cumulative survival rates of lncRNA HEIH high/low expression group were analyzed by Kaplan-Meier curve.Results: LncRNA HEIH in peripheral blood of LUSC and LUAD patients was higher than that in healthy controls, with no evident difference between LUSC and LUAD groups. LUSC and LUAD patients with high lncRNA HEIH expression had larger tumor size, higher CEA level and tumor stage, and higher risk of lymph node metastasis and distal metastasis. LncRNA HEIH had higher diagnostic efficiency than CEA in NSCLC patients. High expression of lncRNA HEIH predicted poor prognosis in patients with NSCLC.Conclusions: High expression of lncRNA HEIH is helpful in the diagnosis of NSCLC and predicts poor prognosis.

scholarly journals High expression of Stabilin-2 predicts poor prognosis in non-small-cell lung cancer

Bioengineered ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 3426-3433
Author(s):  
Juanjuan Yong ◽  
Liyun Huang ◽  
Gengbiao Chen ◽  
Xiaoya Luo ◽  
Hui Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Small Cell ◽  
High Expression ◽  
Small Cell Lung

scholarly journals Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience

2019 ◽  
Vol 13 ◽  
pp. 117955491882131 ◽  
Author(s):  
Maiko Takeda ◽  
Takahiko Kasai ◽  
Maiko Naito ◽  
Akihiro Tamiya ◽  
Yoshihiko Taniguchi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
High Expression ◽  
Small Cell Lung ◽  
Single Institution ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Low Expression

Background: In recent years, the anti-programmed cell death 1 (PD-1) drug pembrolizumab (Keytruda) was approved for treatment of unresectable advanced non-small cell lung cancer (NSCLC) as first- or second-line therapy depending on the clone 22C3-programmed death-ligand 1 (PD-L1) immunohistochemical expression score by the companion diagnostic assay. We herein evaluated 22C3-PD-L1 expression of NSCLC in a single institution experience and compared it with clinicopathologic features. Materials and methods: We assessed 22C3-PD-L1 expressions of 411 patients with NSCLC from our institution, including in past specimens. Programmed death-ligand 1 immunohistochemistry (IHC) testing was performed using the PD-L1 clone 22C3 pharmDx kit (Agilent Technologies/Dako, Carpinteria, CA, USA). Patients were separated into 3 groups with <1% (no expression), 1% to 49% (low expression), or ⩾50% (high expression) positive tumor cells. Results: In all, 137 patients (33%) did not express PD-L1, 155 (38%) showed low expression, and 119 (29%) demonstrated high expression. Archival samples showed lower PD-L1 expression than that of recent samples, and the ratios of no expression case significantly increased by using paraffin blocks embedded particularly in more than 4 years ago. Programmed death-ligand 1 positivity was significantly associated with male sex, smoking, higher tumor grade, squamous cell carcinoma in histologic type, wild-type EGFR, and ALK rearrangement positive. Conclusions: The rate of 22C3-PD-L1 expression of NSCLC detected in this study was similar to the frequencies of the previous reports, although the ratio of expression case decreased when using old paraffin blocks.

scholarly journals High SMARCA5 Expression is Associated With Poor Prognosis in Patients With Non-Small Cell Lung Cancer

2020 ◽  
Author(s):  
Zhi-Qiang Yang ◽  
yuanyuan wen ◽  
Hai-Feng Li ◽  
Lue Li ◽  
Hui He
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Small Cell ◽  
High Expression ◽  
Biological Behavior ◽  
Human Lung Cancer ◽  
Small Cell Lung ◽  
Proliferation And Invasion

Abstract Background: SMARCA5 has been proved to play the role of oncogene in various types of tumors. The purpose of our study was to study the relationship between the expression of SMARCA5 and the prognosis of patients with Non-small cell lung cancer(NSCLC), and to investigate the effect of silencing the expression of SMARCA5 on the biological behavior of NSCLC. Methods：Immunohistochemistry method was adopted to detect to the expressions of SMARCA5 proteins in NSCLC and normal lung tissues. The correlation between the expression of SMARCA5 and clinicopathological factors and survival prognosis of patients with NSCLC were analyzed by statistical methods. Western blot and RT-PCR were used to detect the expression of SMARCA5 in normal human bronchial epithelial cell line (HBE) and human lung cancer cell lines (A549, Lu165, SK-MES-1 and NCI-H520). SMARCA5 siRNA was employed to silence the the expression of SMARCA5. MTT and Transwell methods were used to detect the proliferation and invasion of lung cancer cells.Results: SMARCA5 protein were highly expressed in 78 (59.5%) NSCLC tissues. SMARCA5 mRNA (P<0.05) and protein (P<0.05) were significantly higher in NSCLC tissues than in the adjacent normal tissues. SMARCA5 expression was significantly associated with poorly differentiation (P<0.001), advanced TNM stage (P<0.001), and pleural invasion (P=0.032). Meanwhile, High expression of SMARCA5 was associated with poor prognosis of NSCLC patients. Knockdown of SMARCA5 expression inhibited cell growth and invasion in NSCLC. Conclusion: High expression of SMARCA5 is associated with poor prognosis in patients with NSCLC, and SMARCA5 can increase activity of proliferation and invasion in NSCLC cells. SMARCA5 may play a decisive role in tumorigenesis of NSCLC.

scholarly journals NUF2 Correlates with Poor Prognosis in Non-Small Cell Lung Cancer: A Systematic Multi-Omics Analysis

2020 ◽  
Author(s):  
Mengqing Chen ◽  
Yue Zhang ◽  
Yuling Liang ◽  
Dan Luo ◽  
Wenjun Wang
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Differential Expression ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Small Cell ◽  
High Expression ◽  
Small Cell Lung ◽  
Omics Analysis ◽  
Differential Expression Genes

Abstract Background: Lung cancer is one of the most common malignant tumors and the leading causes of cancer-related deaths worldwide. As a component of the nuclear division cycle 80 complex, NUF2 is a part of the conserved protein complex related to the centromere. Although the high expression of NUF2 has been reported in many different types of human cancers, no studies have conducted systematic multi-omics analysis on NUF2 in non-small cell lung cancer.Methods: In this analysis, NUF2 difference analysis in non-small cell lung cancer were evaluated in GEO, TCGA, Oncomine, UALCAN databases, and a prognosis analysis of NUF2 based on Kaplan-Meier was performed. R language was used to analyze the differential expression genes, functional Annotation and protein-protein interaction. GSEA analysis of differential expression genes were also carried out. Mechanism analysis about exploring the characteristic of NUF2, multi-omics and correlation analysis were carried out using UALCAN, cBioportal, GEPIA and TIMER.Results: The expression of NUF2 in tumor tissues was significantly higher than that in normal tissues. The analysis of TCGA and UALCAN database samples proved that NUF2 expression was connected with stage, TNM stage and smoking habits. Meanwhile, the overall survival curve also validated that high expression of NUF2 indicated poor prognosis. Furthermore, immune infiltration analysis showed NUF2 had correlation with immune cells and NUF2 altered group had a poor prognosis than unaltered group in non-small cell lung cancer.Conclusion: Our results demonstrated that data mining efficiently reveals NUF2 expression and potential regulatory mechanism in non-small cell lung cancer, laying a foundation for further study of the role of NUF2 in diagnosis and treatment in non-small cell lung cancer.

Sign in / Sign up

Export Citation Format

Share Document